Trial Profile
A randomised, open, parallel-group, multicentre study to examine the safety and effectiveness of three doses of argatroban as anticoagulant in combination with clopidogrel and aspirin in patients undergoing elective percutaneous coronary intervention in comparison with unfractionated heparin, clopidogrel and aspirin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Argatroban (Primary) ; Aspirin; Clopidogrel; Heparin
- Indications Coronary artery disease; Thrombosis; Unstable angina pectoris
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma America
- 14 Apr 2011 Results published in the International Journal of Cardiology.
- 03 Sep 2007 New trial record.